BofA Downgrades Biohaven to Underperform, Cuts Price Target to $11 on Kv7 Risks
Analyst highlights competition risk in Kv7 epilepsy program and cuts peak sales forecast.
/ 77 items
#XY Analyst Up/Down↓
Rademikibart Breakthrough Potential: Piper Sandler Sees First-in-Class Opportunity at CNTB
Rademikibart offers first-mover potential in acute asthma & COPD with major Phase 2 data coming in September 2026.
Jefferies Upgrades Tango Therapeutics to Buy, Lifts Price Target to $60 on Promising Pancreatic Cancer Data
Jefferies turned bullish on Tango Therapeutics as early cancer data and big market potential lifted its price target.
Cantor Fitzgerald Initiates Overweight Coverage on Silence Therapeutics, Calls Stock “Materially Undervalued”
The firm initiated Overweight coverage citing strong divesiran Phase 2 potential and 160%+ upside.
Leerink Initiates Outperform on Altimmune: Pemvidutide Poised for MASH Success with $10 Target
Pemvidutide demonstrates strong MASH resolution, weight loss, and cardiometabolic benefits, with significant analyst upside.
Wall Street Initiates Coverage on IMMX, PRAX & RNA with Buy Ratings – Morgan Stanley Downgrades ENGN
BofA initiates coverage on IMMX with a Buy rating and $27 price target. RBC starts PRAX with Outperform ($449 PT), while Cantor begins coverage on RNA. Morgan Stanley downgrades ENGN to Underweight.